---
title: "Top 10 HK Stock Losers (10.27)"
description: "YEEBO (INT'L H)(00259) fell 22.38%, with a trading turnover 60.7 Million HKD, and a year-to-date rose 275.8%. SDHG(00412) fell 18.64%, with a trading turnover 256.6 Million HKD, and a year-to-date fel"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262843029.md"
published_at: "2025-10-27T08:31:11.000Z"
---

# Top 10 HK Stock Losers (10.27)

> YEEBO (INT'L H)(00259) fell 22.38%, with a trading turnover 60.7 Million HKD, and a year-to-date rose 275.8%. SDHG(00412) fell 18.64%, with a trading turnover 256.6 Million HKD, and a year-to-date fell 70.4%. GUAN CHAO HLDGS(01872) fell 13.91%, with a trading turnover 15.5 Million HKD, and a year-to-date rose 485.6%.

Hang Seng Index has rose 1.05%, with a year-to-date rose 31.8%; Hang Seng TECH Index has rose 1.83%, with a year-to-date rose 38.1%.

YEEBO (INT'L H)(00259) fell 22.38%, with a trading turnover 60.7 Million HKD, and a year-to-date rose 275.8%.

SDHG(00412) fell 18.64%, with a trading turnover 256.6 Million HKD, and a year-to-date fell 70.4%.

GUAN CHAO HLDGS(01872) fell 13.91%, with a trading turnover 15.5 Million HKD, and a year-to-date rose 485.6%.

### Related Stocks

- [00259.HK - YEEBO (INT'L H)](https://longbridge.com/en/quote/00259.HK.md)
- [00412.HK - SDHG](https://longbridge.com/en/quote/00412.HK.md)
- [01872.HK - GUAN CHAO HLDGS](https://longbridge.com/en/quote/01872.HK.md)
- [02367.HK - GIANT BIOGENE](https://longbridge.com/en/quote/02367.HK.md)
- [00931.HK - CHINA HK POWER](https://longbridge.com/en/quote/00931.HK.md)
- [02591.HK - INNOGEN-B](https://longbridge.com/en/quote/02591.HK.md)
- [09878.HK - HUITONGDA NET](https://longbridge.com/en/quote/09878.HK.md)
- [02411.HK - PAGODA GP](https://longbridge.com/en/quote/02411.HK.md)
- [02670.HK - YUNJI](https://longbridge.com/en/quote/02670.HK.md)
- [09688.HK - ZAI LAB](https://longbridge.com/en/quote/09688.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 再鼎醫藥將於 2 月 26 日召開董事會會議，以批准並公佈 2025 年度業績 | 再鼎醫藥有限公司已安排於 2026 年 2 月 26 日召開董事會會議，以批准截至 2025 年 12 月 31 日的經審計財務結果，符合美國通用會計準則（U.S. GAAP）。如果獲得批准，結果將在同一天發佈，並隨後舉行投資者電話會議。公 | [Link](https://longbridge.com/en/news/275665019.md) |
| 早盤趨勢｜鉅子生物多頭信心鬆動，關鍵支撐岌岌可危？ | 1 月 27 日，鉅子生物（2367.HK）盤中弱勢震盪，盤面反覆探底，多次試探 28 元整數關口支撐未果。全天資金持續流出，綠盤成交佔比高，顯示多頭信心逐步鬆動，主力持倉籌碼開始鬆懈。 生物科技板塊過去一週受地方政策分歧影響，持續表現低迷 | [Link](https://longbridge.com/en/news/273815223.md) |
| 匯通達網絡收購目標公司 25% 的股權 | 匯通達網絡有限公司在獲得重組投資協議批准後，已收購目標公司 25% 的股份。此次收購是在 2026 年 2 月 3 日法院裁定目標公司可以繼續其重組計劃之後進行的。儘管關於交易最終實施的相關不確定性仍然存在，匯通達將繼續推進投資協議。隨着重 | [Link](https://longbridge.com/en/news/274634881.md) |
| 深圳百果園在大量使用後尋求刷新股份發行授權 | 深圳百果園集團計劃更新其股份發行授權，以允許發行的新股數量達到其總已發行股本的 20%。這項計劃是在其當前授權被大幅利用之後提出的，後者在 2025 年 10 月成功配售了 2.795 億股新的 H 股。新的授權需要在一次特別股東大會上獲得 | [Link](https://longbridge.com/en/news/274577368.md) |
| 廣州銀諾醫藥-B 獲批啓動寵物糖尿病藥物 Efsubaglutide Alfa 的試驗 | 廣州銀諾醫藥集團已獲得中國農業農村部的批准，開始其寵物糖尿病藥物 Efsubaglutide Alfa 的第一階段臨牀試驗，預計將在 2026 年第一季度開始。該公司認為寵物糖尿病藥物具有顯著的市場潛力，得到了積極的臨牀前數據支持。然而，成 | [Link](https://longbridge.com/en/news/274887236.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.